Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radium Ra 224-labeled calcium carbonate microparticles
- Development stage
- Unknown
- Lead developer
- Oncoinvent
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intraperitoneal
01
Overview
Radspherin (radium Ra 224-labeled calcium carbonate microparticles) is an investigational, receptor-independent, alpha-emitting radiopharmaceutical developed by Oncoinvent for the local treatment of metastatic cancers in body cavities, particularly peritoneal carcinomatosis. It consists of biodegradable calcium carbonate microparticles that act as carriers for the alpha-emitting radionuclide radium-224 (224Ra). Administered intraperitoneally following cytoreductive surgery (with or without hyperthermic intraperitoneal chemotherapy, HIPEC), the microparticles distribute throughout the peritoneal cavity and deliver short-range, high-energy alpha radiation to eliminate residual microscopic disease and free-floating cancer cells while sparing surrounding healthy tissues.
- Brand names
- Radspherin
- Other names
- 224Ra-CaCO3-MP224Ra-labeled calcium carbonate microparticlesalpha-emitting 224Ra calcium carbonate microspheresalpha-emitting224Ra calcium carbonate microspheresalpha-emitting-224Ra calcium carbonate microspheresradium Ra 224-labeled calcium carbonate microspheresradium-224-labeled calcium carbonate microparticlesradium224-labeled calcium carbonate microparticlesradium 224-labeled calcium carbonate microparticles
Beyond the preview
Go deeper on radium Ra 224-labeled calcium carbonate microparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radium Ra 224-labeled calcium carbonate microparticles.